U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue.
More Stories
Brazil rolls out COVID-19 vaccination plan
First Pfizer COVID-19 vaccine shipments to be delivered to US distribution sites starting Monday
CDC advisory panel recommends Covid-19 vaccine for people 16 and over